Novo Nordisk ended the week at \u20ac43.32, notching a 1.29% gain in Friday\u2019s session. The move capped a 30-day stretch that has delivered nearly 17% in returns, powered by a mix of clinical wins, aggressive share repurchases, and cautious analyst optimism. Yet the picture is more nuanced beneath the surface, with a pipeline hiccup in obesity and intensifying competition from Eli Lilly tempering the rally.<\/p>\n
The backbone of the recent uptrend remains the company\u2019s buyback programme. Since February 4, 2026, Novo has repurchased 23,009,179 B?shares at an average price of 270.32 Danish kroner apiece, equating to more than \u20ac830 million in total spending. The current tranche, launched on May 6 under EU safe?harbour rules, targets additional purchases of up to 11.2 billion kroner through February 1, 2027. The programme \u2014 capped at 15 billion kroner over twelve months \u2014 has provided a structural floor for the stock, which had plunged to a March low of \u20ac30.25 before beginning its recovery. At current levels, shares have climbed more than 43% from that trough and now trade above both the 50?day moving average (\u20ac39.51) and the 200?day moving average (\u20ac40.60). The 14?day RSI stands at 66, suggesting elevated but not yet extreme momentum.<\/p>\n
On the research front, the week brought two contrasting signals. At the International Society on Thrombosis and Haemostasis congress in Paris, Novo presented long?term data from the phase 3 extension study FRONTIER4 for Denecimig (Mim8), its subcutaneous prophylaxis candidate for haemophilia A. The results, covering dosing intervals of once monthly, every two weeks, and once weekly, were described by company executives as confirming the drug\u2019s potential irrespective of inhibitor status \u2014 a positive read?through for a pipeline that had faced some scepticism earlier in the year.<\/p>\n